马沃格鲁兰在2期临床试验中减少可卡因使用障碍患者的可卡因使用
这项2期随机安慰剂对照试验纳入68名可卡因使用障碍成人,按1:1随机接受口服马沃格鲁兰滴定至每日两次200mg或安慰剂治疗98天。主要终点为治疗期间可卡因使用天数比例,马沃格鲁兰较安慰剂降低可卡因使用(协方差分析P=0.021),尿苯甲酰爱康宁浓度较低(P=0.025),酒精消耗减少(P=0.072)。
要点
- 马沃格鲁兰组可卡因使用天数比例较安慰剂组降低,协方差分析P=0.021。
- 马沃格鲁兰组尿苯甲酰爱康宁浓度低于安慰剂组(P=0.025)。
- 治疗组酒精消耗减少(P=0.072),不良事件为头痛、头晕和恶心。
核心结论
- 在这项小型短期试验中,马沃格鲁兰减少了慢性可卡因使用障碍患者的可卡因和酒精使用。
研究设计与样本
- 2期随机安慰剂对照临床试验纳入68名可卡因使用障碍成人,按1:1随机分配至口服马沃格鲁兰滴定至每日两次200mg组或安慰剂组,治疗98天。
主要发现
- 治疗结束时马沃格鲁兰减少可卡因使用的后验概率为:治疗差异<0时≥99.0%,治疗差异<-10%时≥36.6%。
- 马沃格鲁兰与安慰剂的差异经协方差分析P=0.021。
- 马沃格鲁兰组尿苯甲酰爱康宁浓度低于安慰剂组(P=0.025)。
- 治疗组酒精消耗减少(P=0.072)。
- 完成最终治疗访视的患者比例:随机集76%,安全性分析集79%。
局限性
- 原文述本试验为小型且短期试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabotropic glutamate receptor 5 (mGluR5) is involved in cocaine reward processing and addiction. Preclinical studies suggest that blocking this receptor inhibits cocaine self-administration and seeking behavior in rodents. We assessed a selective noncompetitive antagonist of mGluR5 called mavoglurant in a phase 2 randomized, placebo-controlled clinical trial of 68 adults with cocaine use disorder. Study participants were randomly assigned in a 1:1 ratio to an up-titrating schedule of oral mavoglurant twice daily up to 200 mg for 98 days or placebo. The primary end point was the proportion of cocaine use days over the treatment period assessed by a retrospective self-report using Timeline Followback. Secondary end points were urine analysis of the cocaine metabolite benzoylecgonine and alcohol use measured by Timeline Followback assessment. Exploratory end points included testing for cocaine and alcohol metabolites in hair samples. The posterior probability of mavoglurant reducing cocaine use at the end of treatment was ≥99.0% for a treatment difference <0 and ≥36.6% for a treatment difference <-10%. The difference between mavoglurant and placebo was also assessed using analysis of covariance (P = 0.021). Urine benzoylecgonine concentration was lower in the mavoglurant-treated group versus placebo (P = 0.025); there was reduced alcohol consumption in the treatment group (P = 0.072). Seventy-six percent (randomized set) and 79% (safety analysis set) of patients completed the final treatment visit. Adverse events in the treatment group were headache, dizziness, and nausea. In this small and short trial, mavoglurant reduced cocaine and alcohol use in patients with chronic cocaine use disorder.
引用
- Gomez-Mancilla B, Dürsteler KM, Vogel M, et al. Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial. Sci Transl Med. 2025. PMID: 40173260. doi:10.1126/scitranslmed.adi4505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。